These AD-correlated proteomic analyses have unique strengths in systematic elucidation of G9a-mediated mechanisms of AD pathogenesis and MS1262 drug action, including drug-affected pathways from which we can derive new AD-specific biomarkers of drug effects. This evidence concerns the gene EHMT2 and Alzheimer disease.